Moderna returns to oncology
Three off-the-shelf mRNA therapies join intismeran autogene.
Vepdegestrant’s promise narrows
Arvinas and Pfizer abandon first-line atirmociclib combo plans only disclosed in January.
CDH17 becomes flavour of the month
Antibody-drug conjugates hitting this target abound.
AACR 2025 – an academic reminder about Jemperli
An MSKCC study continues to show a 100% response rate in pre-operative rectal cancer.
AACR 2025 – BioNTech sees its first combo glimmers
A BNT327 and BNT325 combo shows promise in platinum-resistant ovarian cancer.
AACR 2025 – a requiem for Roche's TIGIT
Survival in Skyscraper-01 deteriorated, and bore no relation to the Cityscape result.
